SKP.L Regulatory News (SKP)

8 Aug 2006 14:45

Skyepharma PLC08 August 2006 For Immediate Release 8 August 2006 SkyePharma PLC Change of Auditor LONDON, UK, 8 August 2006 - SkyePharma PLC (LSE: SKP; NASDAQ:SKYE) announcesthat following completion of the audit of the Company's financial statements forthe year ended 31 December 2005 and the preparation and filing with the SEC ofits 2005 Annual Report on Form 20-F, PricewaterhouseCoopers LLP ("PwC") hasgiven notice of its resignation as auditor. In its resignation letter PwC statedthat: "Pursuant to Section 394 of the Companies Act 1985, we confirm that thereare no circumstances connected with our resignation which we consider should bebrought to the notice of the shareholders or creditors of Skyepharma PLC." SkyePharma's Audit Committee has invited tenders from certain qualified auditingfirms and the Company will make a further announcement in due course when a newauditor has been appointed. It is anticipated that the new auditor will beresponsible for reviewing the unaudited interim results for the six months ended30 June 2006, which are expected to be announced in late September 2006. PwC has been SkyePharma's auditor for the past ten years. PwC's resignationcoincides with the lead audit partner's required rotation after five years underthe Auditing Practices Board's Ethical Standards guidelines. For further information please contact: SkyePharma PLC +44 207 491 1777Peter Laing, Director of Corporate Communications +44 207 491 5124Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000Tim Anderson / Mark Court / Rebecca Skye Dietrich About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now twelve approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. This information is provided by RNS The company news service from the London Stock Exchange